Analyst Ratings for [CRL] Charles River Laboratories International, Inc.

10/6/25	Upgrades	Mkt Perform Outperform	X
CRL Charles River William Blair
10/2/25	Upgrades	Eq Weight Overweight	X
CRL Charles River Barclays
$195
9/9/25	Upgrades	Hold Buy	X
CRL Charles River Jefferies
$195
7/9/25	Upgrades	Neutral Buy	X
CRL Charles River Citigroup
$200
5/23/25	Upgrades	Neutral Buy	X
CRL Charles River Redburn Atlantic
$182
5/14/25	Upgrades	Hold Buy	X
CRL Charles River TD Cowen
$179
5/8/25	Upgrades	In-line Outperform	X
CRL Charles River Evercore ISI
$170
3/21/25	Downgrades	Buy Neutral	X
CRL Charles River Goldman
$190 $170
3/4/25	Upgrades	Sell Neutral	X
CRL Charles River Citigroup
$155 $175
3/3/25	Upgrades	Sell Neutral	X
CRL Charles River Redburn Atlantic
$188
1/22/25	Downgrades	Outperform Mkt Perform	X
CRL Charles River William Blair
1/17/25	Downgrades	Buy Neutral	X
CRL Charles River UBS
$250 $185
11/18/24	Downgrades	Hold Underperform	X
CRL Charles River CLSA
$164
11/7/24	Upgrades	Underperform Hold	X
CRL Charles River CLSA
$205
10/23/24	Initiated	Underperform	X
CRL Charles River CLSA
$167
10/14/24	Initiated	Sell	X
CRL Charles River Redburn Atlantic
10/7/24	Downgrades	Outperform In-line	X
CRL Charles River Evercore ISI
$225 $190
10/2/24	Downgrades	Buy Neutral	X
CRL Charles River BofA Securities
$250 $215
10/1/24	Downgrades	Neutral Sell	X
CRL Charles River Citigroup
$215 $175
8/8/24	Downgrades	Overweight Neutral	X
CRL Charles River JP Morgan
$270 $205
8/8/24	Downgrades	Outperform Neutral	X
CRL Charles River Robert W. Baird
$239 $191
6/28/24	Downgrades	Buy Hold	X
CRL Charles River Argus
6/7/24	Initiated	Neutral	X
CRL Charles River Mizuho
$235
6/6/24	Initiated	Buy	X
CRL Charles River Goldman
$290
2/15/24	Downgrades	Buy Neutral	X
CRL Charles River Guggenheim
9/13/23	Initiated	Market Perform	X
CRL Charles River TD Cowen
$212
7/10/23	Downgrades	Buy Neutral	X
CRL Charles River Citigroup
$260 $225
2/23/23	Upgrades	Neutral Buy	X
CRL Charles River Guggenheim
$255
1/12/23	Downgrades	Buy Hold	X
CRL Charles River Jefferies
9/30/22	Upgrades	Hold Buy	X
CRL Charles River Jefferies
$240
8/25/22	Initiated	Outperform	X
CRL Charles River Credit Suisse
$285
8/4/22	Downgrades	Overweight Eq-Weight	X
CRL Charles River Morgan Stanley
$350 $250
5/24/22	Initiated	Neutral	X
CRL Charles River Guggenheim
4/25/22	Downgrades	Buy Hold	X
CRL Charles River Jefferies
$370 $280
4/7/22	Initiated	Overweight	X
CRL Charles River Stephens
$377
6/10/19	Initiated	Outperform	X
CRL Charles River SVB Leerink
$155
4/30/19	Resumed	Outperform	X
CRL Charles River Evercore ISI
$160
12/14/18	Initiated	Buy	X
CRL Charles River Deutsche Bank
10/9/18	Initiated	Neutral	X
CRL Charles River UBS
8/23/18	Upgrades	Mkt Perform Outperform	X
CRL Charles River Raymond James
7/17/18	Upgrades	Sec Perform Outperform	X
CRL Charles River RBC Capital Mkts
6/15/18	Upgrades	Sec Weight Overweight	X
CRL Charles River KeyBanc Capital Mkts
2/14/18	Upgrades	Hold Buy	X
CRL Charles River SunTrust

CRL Charles River Laboratories International, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.